LeddarTech and Prospector Capital Corp. Announce Effectiveness of Registration Statement and December 13, 2023 Extraordinary General Meeting to Approve Business Combination

QUEBEC CITY, Dec. 04, 2023 (GLOBE NEWSWIRE) — LeddarTech Inc.® (“LeddarTech” or the “Company”), an automotive software company that provides patented disruptive AI-based low-level sensor fusion and perception software technology for ADAS and AD, and Prospector Capital Corp. (“Prospector”) (NASDAQ: PRSR, PRSRU, PRSRW), a publicly traded special-purpose acquisition company led by former Qualcomm President Derek […]

Continue Reading

LeddarTech et Prospector Capital Corp. annoncent l’entrée en vigueur de la déclaration d’enregistrement et la tenue d’une assemblée générale extraordinaire le 13 décembre 2023 visant l’approbation du regroupement d’entreprises

QUÉBEC, 04 déc. 2023 (GLOBE NEWSWIRE) — LeddarTech Inc.® (« LeddarTech » ou l’« Entreprise »), une société de logiciels automobiles qui fournit des technologies logicielles de fusion bas niveau de capteurs et de perception reposant sur l’IA, innovatrices et brevetées pour systèmes avancés d’aide à la conduite (systèmes ADAS) et de conduite autonome (systèmes AD), et Prospector Capital […]

Continue Reading

Zenas BioPharma Strengthens Executive Leadership with Appointment of Jennifer Fox as Chief Business Officer and Chief Financial Officer and Tanya Fischer, M.D., PhD. as Head of R&D and Chief Medical Officer

Expanded strategic and operational leadership positions Zenas for growth as obexelimab advances in late-stage clinical trials for multiple potential I&I indications WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) —  Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of inflammation and immunology (I&I) directed therapies, today announced the […]

Continue Reading

Zenas BioPharma Fortalece a Liderança Executiva com a Nomeação de Jennifer Fox como Diretora de Negócios e Financeira, e de Tanya Fischer, MD, Ph.D. como Dirigente de P&D e Médica

Com a expansão dessa liderança estratégica e operacional, a Zenas se posiciona para o crescimento esperado com o avanço do voltadas para inflamações e imunologia nos ensaios clínicos em estágio avançado de várias indicações potenciais de I&I WALTHAM, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) — A Zenas BioPharma, uma empresa biofarmacêutica global comprometida em se […]

Continue Reading

Zenas BioPharma renforce sa direction avec la nomination de Jennifer Fox en tant que Chief Business Officer et Chief Financial Officer et de Tanya Fischer, M.D., PhD., en tant que Head of R&D et Chief Medical Officer

Le renforcement du leadership stratégique et opérationnel permet à Zenas de se développer et les essais cliniques en phase avancée sur l’obéxélimab progressent, pour de multiples indications potentielles dans l’I&I WALTHAM, Massachusetts, 04 déc. 2023 (GLOBE NEWSWIRE) — Zenas BioPharma, un laboratoire biopharmaceutique d’envergure mondiale déterminé à devenir un leader dans le développement et la commercialisation […]

Continue Reading